טוען...
ABS38: Add-on omalizumab significantly improves quality of life in patients with severe persistent allergic (IgE-mediated) asthma
INTRODUCTION: Patients with severe persistent allergic asthma experience frequent serious exacerbations and daily symptoms that diminish health-related quality of life (QoL). AIMS AND OBJECTIVES: To evaluate effects on QoL of add-on omalizumab, an anti-IgE therapy. Subjects and method: A pooled anal...
שמור ב:
| הוצא לאור ב: | Prim Care Respir J |
|---|---|
| Main Authors: | , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Nature Publishing Group
2006
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6730753/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.pcrj.2006.04.137 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|